ASX healthcare share rockets 9% on upgraded profit growth guidance

This healthcare player has confirmed high growth for FY25.

| More on:
a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare share Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) has rocketed out of the blocks on Friday after the company provided an update on its FY25 profit guidance.

Shares are racing 9% higher from the open and are fetching $32.00 apiece as investors react positively to the news.

Fisher & Paykel has been on a tear this year with the stock up 46.6% in that time, so today's price action continues this uptrend.

Let's see what the company posted.

Created with Highcharts 11.4.3Fisher & Paykel Healthcare PriceZoom1M3M6MYTD1Y5Y10YALL1 Aug 202323 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '23Sep '23Jan '24Jan '24May '24May '24www.fool.com.au

ASX healthcare updates H1 guidance

After updating the market on its business performance so far in FY25, the ASX healthcare share revised its projections higher.

Revenue is now projected to fall between $940 million and $950 million for the first half of FY25, marking an 18% increase compared to H1 last year.

Fisher & Paykel management also expects net profits to jump by 44% in the first half to $160 million, which is at the upper end of estimates.

This comes after it grew sales by 10% in FY24, leading to a 6% growth in net profit for the year. As such, the company expects big growth this financial year.

Management said the growth was driven by several factors, including successful new product launches and a higher-than-expected hospital census in both the Northern and Southern Hemispheres.

The company has also made notable strides in improving its gross margins. CEO Lewis Gradon highlighted this progress:

The year to date has begun strongly across all products and regions. In the Hospital product group, contributions include ongoing change in clinical practice, and a good response to new product introductions.

In addition, early indications are that the year to date includes a relatively high hospital census during the period in both the Northern and Southern Hemispheres as Northern Hemisphere seasonal hospitalisations persisted into the beginning of this current financial year and hospitals have returned to more normalised staffing and capacity.

This has seen investors gobbling up the ASX healthcare share en masse today, likely positioning for this expected growth.

Positive updates for the full year, too

Fisher & Paykel has also revised its full-year guidance. The ASX healthcare share didn't change its revenue expectations – it still expects sales of $1.9 billion to $2.0 billion.

However, it raised its profit forecasts by around $10 million, now estimating the bottom line at between $320 million and $370 million.

The company expects to maintain its current business momentum, supported by continued changes in clinical practice and the success of new products. CEO Gradon expressed optimism about the year ahead:

We expect the remainder of the financial year for our Hospital product group to have similar underlying contributions from changes to clinical practice and new product introductions.

We have not changed our view on the revenue guidance range for the full year due to the additional and variable impact of Northern Hemisphere seasonal hospitalisation rates, which historically occur towards the end of our second half.

Gradon described Fisher & Paykel's hospital products as "market leaders", and said that its sleep apnea masks were getting positive reviews.

Wilson's rated the stock a buy earlier this month, while Equity Trustees has placed the ASX healthcare stock on its 'shopping list' of top-quality businesses to consider for the long term.

ASX healthcare share snapshot

Fisher & Paykel's share price has been on a tear this year. The ASX healthcare share has just updated its outlook for both the first half and full year for FY25.

Shares in the company have climbed 54% in the last 12 months and are up 46.6% year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »